Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory hematological malignancies, producing deep and durable responses in B-cell acute lymphoblastic leukemia, aggressive B-cell non-Hodgkin lymphomas, and multiple myeloma. Nevertheless, antigen escape, limited in vivo per...
Alaa A. A. Aljabali, Mohammad A. Obeid, A. Alqudah et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.